

## Papers in peer-reviewed journals

**Sawyer LM**, Wonderling D, Jackson K, Murphy R, Samarasekera EJ, Smith CH. Biological Therapies for the Treatment of Severe Psoriasis in Patients with Previous Exposure to Biological Therapy: A Cost-Effectiveness Analysis. *Pharmacoeconomics* 2014 Dec 20.

**Diamantopoulos A**, Finckh A, Huizinga T, **Sungher DK**, **Sawyer L**, Neto D, et al. Tocilizumab in the treatment of rheumatoid arthritis: a cost-effectiveness analysis in the UK. *Pharmacoeconomics* 2014 Aug;32(8):775-87.

**Sawyer L**, Azorin JM, **Chang S**, **Rinciog C**, Guiraud-Diawara A, Marre C, et al. Cost-effectiveness of asenapine in the treatment of bipolar I disorder patients with mixed episodes. *J Med Econ* 2014 Jul;17(7):508-19.

Monreal M1, Folkerts K, **Diamantopoulos A**, Imberti D, Brosa M. Cost-effectiveness impact of rivaroxaban versus new and existing prophylaxis for the prevention of venous thromboembolism after total hip or knee replacement surgery in France, Italy and Spain. *Thromb Haemost.* 2013 Oct 31;110(5):987-94.

Samarasekera EJ, **Sawyer L**, Wonderling D, Tucker R, & Smith CH. Topical therapies for the treatment of plaque psoriasis: systematic review and network meta-analyses. *British Journal of Dermatology.* 2013; 168: 954-967.

**Sawyer L**, Samarasekera EJ, Wonderling D, & Smith CH (2013). Topical therapies for the treatment of localized plaque psoriasis in primary care: a cost-effectiveness analysis. *British Journal of Dermatology*, 2013; 168: 1095-1105.

Samarasekera E, **Sawyer L**, Parnham J, Smith CH, Guideline Development Group. Assessment and management of psoriasis: summary of NICE guidance. *BMJ.* 2012 Oct 24;345:e6712.

**Diamantopoulos A**, **Sawyer L**, Ogale S, Dejonckheere F. Validity of cost and utility results? *Pharmacoeconomics.* 2012 Oct 1;30(10):977; author reply 977-8.

McDonald H, **Diamantopoulos A**, Wells P, Lees M, Folkerts K, Forster F, Ananthapavan J. Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis using the Ontario Ministry of Health Perspective. *J Med Econ.* 2012;15(5):817-28.

**Diamantopoulos A**, Benucci M, Capri S, Berger W, Wintfeld N, Giuliani G, Ricciardi W. Economic evaluation of tocilizumab combination in the treatment of moderate to severe rheumatoid arthritis in Italy. *J Med Econ.* 2012;15(3):576-85. Epub 2012 Mar 9.

Duran A, Sengupta N, **Diamantopoulos A**, et al. Cost Effectiveness of Rivaroxaban versus Enoxaparin for Prevention of Post-Surgical Venous Thromboembolism from a US Payer's Perspective. *Pharmacoeconomics.* 2012 Feb 1;30(2):87-101.

Duran A, Sengupta N, **Diamantopoulos A**, et al. Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective. *J Med Econ*. 2011;14(6):824-34.

Ryttberg L, **Diamantopoulos A**, Forster F, Lees M, Frascchke A, Björholt I. Cost-effectiveness of rivaroxaban versus heparins for prevention of venous thromboembolism after total hip or knee surgery in Sweden. *Expert Rev Pharmacoecon Outcomes Res*. 2011 Oct;11(5):601-15.

Lereun C, Wells P, **Diamantopoulos A**, Rasul F, Lees M, Sengupta N. An indirect comparison, via enoxaparin, of rivaroxaban with dabigatran in the prevention of venous thromboembolism after hip or knee replacement. *J Med Econ*. 2011; 14(2): 238-44. Epub 2011 Mar 9.

**Diamantopoulos A**, Lees M, Wells PS, Forster F, Ananthapavan J, McDonald H. Cost-Effectiveness of Rivaroxaban versus Enoxaparin for the Prevention of Postsurgical Venous Thromboembolism in Canada. *Thromb Haemost*. 2010 Oct;104(4):760-70.

Kielhorn A, Porter D, **Diamantopoulos A**, Lewis G. UK cost-utility analysis of rituximab in patients with rheumatoid arthritis that failed to respond adequately to a biologic disease-modifying antirheumatic drug. *Curr Med Res Opin*. 2008; 24(9): 2639-50.

Brown B, **Diamantopoulos A**, Bernier J, Schöflski P, Hieke K, Mantovani L, Launois R, Griebisch I, Robinson P. An economic evaluation of cetuximab combined with radiotherapy for patients with locally advanced head and neck cancer in Belgium, France, Italy, Switzerland and the United Kingdom. *Value in health*. 2008; 11(5): 791-799.

Tang CH, Liu JT, **Chang CW**, Chang WY. Willingness to pay for drug abuse treatment: result from a contingent valuation study in Taiwan. *Health Policy*. 2007; 82(2): 251-262.

**Neophytou I**, Harvey R, Lawrence J, Marsh P, Panaretou B, Barlow D. (2007). Eukaryotic integral membrane protein expression utilizing the Escherichia coli glycerol-conducting channel protein (GlpF). *Appl Microbiol Biotechnol*; 77(2):375-81.

Tilden DP, Mariz S, O'Bryan-Tear G, Bottomley J, **Diamantopoulos A**. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. *Pharmacoeconomics*. 2007; 25(1): 39-54

### **Podium presentations**

**Diamantopoulos A**, LeReun C, Rasul F, Lees M, Kubin M. Indirect comparisons of rivaroxaban vs alternative prophylaxes for the prevention of venous thromboembolism (VTE) in patients undergoing total hip replacement (THR) or total knee replacement (TKR). Fifth Annual Meeting of Health Technology Assessment International. Montreal, Canada. July 2008

**Chang SCW**. Comparing economic and non-economic outcome measurements in the evaluation of drug misuse interventions. Alcuin Research Resource Centre (ARRC) Conference, University of York. York, UK. July 2009

Pompen M, **Diamantopoulos A**, Kievit W, Moers R, Kielhorn A. Economic consequences of providing rituximab as a treatment alternative for rheumatoid arthritis in the Netherlands. ISPOR 10th Annual European Congress. Dublin, Ireland. October 2007

### **Poster presentations**

Harland D, **Diamantopoulos A**, **Chang S**, **Sawyer L** Abthera for the treatment of severe ANCA-Associated vasculitis – A cost utility model for the United Kingdom. ISPOR 17th Annual European Congress, Amsterdam Netherlands, 8-12 November 2014

**Rinciog C**, Myrén KJ, Aldén M, **Diamantopoulos A**, **LeReun C**. An Indirect Treatment Comparison of Cabozantinib vs. Vandetanib in Progressive Medullary Thyroid Cancer (MTC). ISPOR 17th Annual European Congress, Amsterdam Netherlands, 8-12 November 2014

**Sawyer L**, **Chang S**, **Diamantopoulos A**, Dejonckheere F. Efficacy Of Novel DMARDs In Early Active Rheumatoid Arthritis: An Indirect Comparison. Value in Health 2014 Nov; 17(7): A374

**Sawyer L**, **Chang S**, **Diamantopoulos A**, Dejonckheere F. Efficacy Of Biologic Treatments In Early Active Rheumatoid Arthritis: An Indirect Comparison. Arthritis Rheum 2014 Oct; 66(Suppl 10).

**Chang S**, **Sawyer L**, Dejonckheere F. Indirect Comparison of Tocilizumab and Tofacitinib in Patients with Rheumatoid Arthritis. Arthritis Rheum 2014 Oct; 66(Suppl 10).

**Sawyer L**, **Chang S**, **Diamantopoulos A**, Dejonckheere F. Efficacy of Biologic Treatments in Early Active Rheumatoid Arthritis: an Indirect Comparison. Ann Rheum Dis 2014; 73(Suppl 2): 950

**Sawyer L**, **Diamantopoulos A**, Brunner HI, De Benedetti F, Ruperto N, Dejonckheere F, Keane C. Efficacy Of Biologic Treatments In Juvenile Idiopathic Arthritis With a Polyarticular Course: An Indirect Comparison. Arthritis Rheum 2013 Oct; 65 (10 Supplement):S119

**Sawyer L**, **Diamantopoulos A**, Brunner HI, De Benedetti F, Ruperto N, Dejonckheere F, Keane C. Efficacy of Biologic Treatments in Juvenile Idiopathic Arthritis with a Polyarticular Course: An Indirect Comparison. Pediatric Rheumatology 2013, 11(Suppl 2):P82

Rogers J, **Chang S**, Quiroz ME, Madden T, **Diamantopoulos A**, Mollenkopf SA. The cost-effectiveness of detecting arrhythmia with implantable loop recorders in the United States of America. Research poster for the ISPOR 19th Annual International Meeting.

Azorin JM, **Sawyer L**, **Chang S**, **Rinciog C**, Guiraud-Diawara A, Marre C, Hansen K. Cost-Effectiveness of Asenapine in the Treatment of Bipolar Disorder I Patients with Mixed Episodes. 2013 Nov; 16(7): A549. Research poster for the ISPOR 16th Annual European Congress.

**Chang S**, **Sawyer L**, Dejonckheere F, van Suijlekom-Smit LW, Anink J, **Diamantopoulos A**. Tocilizumab in Polyarticular Juvenile Idiopathic Arthritis – A Cost-Utility Model for the United Kingdom. Value in Health 2013 Nov; 16(7): A564. Research poster for the ISPOR 16th Annual European Congress.

**Sungher DK** & **Diamantopoulos A**. Mapping the Oxford Hip Score (OHS) to EQ-5D: a test of model performance. Research poster for the ISPOR 16th Annual European Congress.

**Diamantopoulos A, Forster F, Evers T.** Clinical impact of treatment persistence in patients with atrial fibrillation. Abstract PCV28 presented at ISPOR 18th Annual International Meeting, New Orleans, USA; May 18-22 2013

**Sawyer L, Diamantopoulos A, Brunner HI, De Benedetti F, Ruperto N, Dejonckheere F, Keane C.** Efficacy of Biologic Treatments in Juvenile Idiopathic Arthritis with a Polyarticular Course: An Indirect Comparison. *Ann Rheum Dis* 2013;72:A740-A741.

Harland D, Gibbons C, **Diamantopoulos A**, Pang H, Huertas C, Dejonckheere F. Tocilizumab in Methotrexate-Intolerant or contraindicated Patients – A Cost-Utility Model for the UK. Research poster for the ISPOR 15th Annual European Congress.

Monteiro I, Cafe A, Encarnacao R, **Diamantopoulos A**, Dejonckheere F. Cost-Utility of Tocilizumab Monotherapy in Methotrexate Intolerant/Contra-Indicated, Moderate/Severe Rheumatoid Arthritis Patients in Portugal. Research poster for the ISPOR 15th Annual European Congress.

**Sungher DK, Folkerts K, Mcdonald H, Diamantopoulos A.** Venous Thromboembolism: A Systematic Literature Review to Identify Multi-Attribute Utility Values for Use in Economic Models. Research poster for the ISPOR 15th Annual European Congress.

Pereira R, **Diamantopoulos A**, Bielik J, Lees M, Tomek D, Lukac M. Cost-utility analysis of rivaroxaban compared with enoxaparin in prevention of venous thromboembolism after total hip replacement in Slovakia. ISPOR 15th Annual International Meeting.

**Diamantopoulos A, Andrade S, Bernardo A, et al.** Cost-effectiveness of tocilizumab compared to standard therapeutic sequences for the treatment of moderate/severe rheumatoid arthritis (RA) patients in Portugal. Research poster for the ISPOR 14th Annual European Congress. **BEST RESEARCH PRESENTATION POSTER AWARD WINNER**

**Chang S, Sungher D, Diamantopoulos A,** Learning effect in economic evaluations of health care interventions. Research poster for the ISPOR 14th Annual European Congress.

**Diamantopoulos A, Kievit W, De Vries R, Pompen M.** Cost-effectiveness of rituximab in the treatment of RA patients in the Netherlands. Research poster for the ISPOR 14th Annual European Congress.

LeReun C, **Neophytou I, de Vries R, Diamantopoulos A, Pompen M.** A network meta-analysis of biologic treatments in TNF-IR rheumatoid arthritis patients. Research poster for the ISPOR 14th Annual European Congress.

Wieser S, Brühlmann P, Kyburz D, Plessow R, Pletscher M, **Diamantopoulos A, Brügger U.** Cost-effectiveness of Tocilizumab in Switzerland: A Microsimulation Approach. Research poster for the ISPOR 13th Annual European Congress.

**Neophytou I, LeReun C, Diamantopoulos A.** Analysis of inappropriate shocks in implantable cardioverter defibrillator (ICD) devices. Research poster for the ISPOR 13th Annual European Congress.

Wieser S, Brühlmann P, Kyburz D, Plessow R, Pletscher M, **Diamantopoulos A**, Brügger U. Cost-effectiveness of Tocilizumab in Switzerland: A Microsimulation Approach. Poster (Nr. P 25) für den Jahreskongress SGR 2010 in Fribourg angenommen wurde

**Diamantopoulos A**, Forster F, Duran A, Brosa M, Lees M, Gilmour L, Ashley D, Piñol C. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK and Spain. Barcelona, Spain. March 2009.

**Diamantopoulos A**, Forster F, Brosa M, Lees M, Piñol C, Febrer L. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in Spain. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC6.

**Diamantopoulos A**, Forster F, Lees M, McDonald H. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in Canada. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC7

**Diamantopoulos A**, Forster F, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total hip replacement in the UK. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC9.

**Diamantopoulos A**, Forster F, et al. Cost-effectiveness of rivaroxaban versus enoxaparin for thromboprophylaxis after total knee replacement in the UK and Spain. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC8.

Negrini C, **Diamantopoulos A**, Forster F, Lopatriello S, Lees M, Bianchi C, Pedone MP. Prophylaxis with rivaroxaban against venous thromboembolism (VTE): a cost-consequence analysis from the Italian Healthcare Service perspective. ISPOR 11th Annual European Congress, Athens, Greece, 8-11 November 2008, Abstract PHC10.

Kwong L, **Diamantopoulos A**, Forster F, Sengupta N, Lees M. Will Rivaroxaban Be Cost-Effective for Prevention of Venous Thromboembolism after Total Hip Replacement in US Patients? Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1290.

Wells P, **Diamantopoulos A**, Forster F, Lees M, McDonald H Cost-Effectiveness of Rivaroxaban as VTE Prophylaxis after Total Hip Replacement in Canada. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1291.

**Diamantopoulos A**, LeReun C, Rasul F, Lees M, Kubin M, Wells P Indirect Comparisons of Rivaroxaban Versus Alternative Prophylaxes for the Prevention of VTE in Patients Undergoing Total Knee Replacement. Blood (ASH Annual Meeting Abstracts), Nov 2008; 112: 1292.

**Diamantopoulos A**, LeReun C, Rasul F, Lees M, Kubin M. Indirect comparison of rivaroxaban regimens vs standard prophylaxis for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement. 20th International Congress on Thrombosis (ICT). Athens, Greece; 25–28 June 2008.

**Diamantopoulos A**, LeReun C, Rasul F, Lees M, Kubin M. Indirect comparison of rivaroxaban vs standard prophylaxis for the prevention of venous thromboembolism in patients undergoing total hip or total knee replacement. ISPOR 13th Annual International meeting. Toronto, Canada. 2008

Lewis G, Kielhorn A, **Diamantopoulos A**. Cost-effectiveness of rituximab (mabthera) compared with abatacept (orencia) for the treatment of moderate/severe rheumatoid arthritis (RA) in the UK. ISPOR 10th Annual European Congress. Dublin, Ireland. October 2007. **BEST RESEARCH PRESENTATION POSTER AWARD WINNER**

**Diamantopoulos A**, Cottrell S, Lorenzo M. A cost-utility analysis of atomoxetine against current stimulant therapies for the treatment of children with attention deficit/hyperactivity disorder (ADHD) in Germany. ISPOR 10th Annual European Congress, Dublin, Ireland, October 2007

Porter D, Lewis G, Brown B, **Diamantopoulos A**, Kielhorn A, Cost-effectiveness analysis of rituximab as a new therapeutic option for rheumatoid arthritis in the UK. ISPOR 11th Annual international meeting. Philadelphia, PA, USA, May 2006

De Vita S, Giuliani G, **Diamantopoulos A**, Brown B, Kielhorn A. Modelling of the cost-effectiveness of rituximab for treatment of rheumatoid arthritis in Italy. ISPOR 11th Annual international meeting. Philadelphia, PA, USA, May 2006

Kielhorn A, Alvarez C, Aristides M, **Diamantopoulos A**. Using mabthera in patients with rheumatic arthritis in Spain: results of cost-effectiveness data based on micro-simulation. ISPOR 11th Annual international meeting. Philadelphia, PA, USA, May 2006

Brosa M, Robinson P, Brown B, **Diamantopoulos A**. Cost-effectiveness of cetuximab in combination with radiotherapy versus radiotherapy alone in the treatment of locally advanced head and neck cancer in Spain. ISPOR 11th Annual international meeting Philadelphia, PA, USA, May 2006

Schach S, Rubbert A, **Diamantopoulos A**, Aristides M, Kielhorn A Cost implications of introducing rituximab as a new treatment modality for rheumatoid arthritis in Germany. Ann Rheum Dis 2006;65(Suppl II):600

Lewis G, Porter D, Brown B, **Diamantopoulos A**, Kielhorn A. Economic consequences of providing rituximab as a new therapeutic option for rheumatoid arthritis in the UK. Ann Rheum Dis 2006;65(Suppl II):283

Mistry B, McCormick J, **Diamantopoulos A**, Kielhorn A. Cost-utility analysis of rituximab as a new therapeutic option for rheumatoid arthritis patients in Canada. ISPOR 9th Annual European Congress. Copenhagen, Denmark October 2006

**Chang CW**. Comparing cost-effectiveness of interventions to reduce mother-to-child transmission of HIV in South and South-East Asia. ISPOR 2nd Asia-Pacific Conference. Shanghai, China. March 2006

Tilden D, Mariz S, **Diamantopoulos A**, O'Bryan-Tear G. A lifetime modelled economic evaluation comparing pioglitazone and rosiglitazone for the treatment of type 2 diabetes mellitus in the UK. ISPOR 8th Annual European Congress. Florence, Italy 2005

*Updated January 2015*